Erdafitinib(Balversa)

Erdafitinib is a prescription drug that selectively inhibits the tyrosine kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. It received accelerated approval from the U.S. FDA on April 12, 2019, and must be used strictly under medical supervision.

Target

Inhibits the tyrosine kinase activity of FGFR1, FGFR2, FGFR3 and FGFR4.

Dosage and Administration

Route and frequency of Erdafitinib administration: oral, once daily.

Dosage of Erdafitinib should be adjusted according to the patient’s actual condition. For specific adjustments, consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Erdafitinib

Side Effects

Common side effects: dizziness, syncope.

Serious side effects: ocular disorders, symptoms of heart failure, other cardiovascular effects.

Reference article: Side Effects of Erdafitinib

Use in Special Populations

Pregnancy: If you are pregnant or suspect pregnancy, inform your healthcare provider immediately.

Lactation: Do not breastfeed during treatment and for 1 month after the last dose.

Daily Precautions

1. Patients should be instructed to take Erdafitinib tablets once daily, with or without food. They should be advised to swallow Erdafitinib tablets whole. If vomiting occurs, emphasize the importance of taking the next dose on schedule; do not take an extra dose to make up for the vomited dose.

2. If a dose is missed, emphasize the importance of taking it as soon as possible on the same day, and resuming the next scheduled dose on the following day. Do not take an extra dose to compensate for the missed dose.

3. Risk of ocular diseases. Patients should be informed to contact their clinician immediately if any visual changes occur (e.g., blurred vision or vision loss). Emphasize the importance of using artificial tear substitutes or moisturizing lubricating eye gels or ointments at least every 2 hours while awake to prevent or treat dry eye.

from FDA,2024.01